Clinical Trial Search

Primary: Overall Response Rate — 77.8 % of participants with response by PI

Primary: Response Based on Overall Response Rate — 17; 11; 28; 6 Participants

Primary: Overall Response Rate (Main Cohort) — 77.1 percentage of participants — p=<0.001

Primary: Number of Participants With Complete Response of the Combination of Ibrutinib, Fludarabine, and Pembrolizumab in Patients With High-risk and/or Relapsed/Refractory…

Primary: Percentage of Participants Achieving Low Tumor Burden Status With Induction of Obinutuzumab or Obinutuzumab Plus Bendamustine (Debulking Period) — 81.4; 83.9; 88.3; 87.1…

Primary: Change in Gene Expression Post Chemo — 30; 50 Percent change in cells

Primary: Complete Remission Rate in Participants Not Previously Treated With BCRi Therapy - Primary Analysis — 35.1 percentage of participants — p=<0.001

Primary: Number of Participants With Complete Response (CR) — 14 participants

Primary: Rate of Confirmed MRD-negative Response — 0 proportion of patients

Primary: Overall Objective Response — 10; 5; 26; 4 Participants

Primary: PFS (Progression Free Survival) — NA; 18.9 Months — p=<0.0001

Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) — 116; 11 Participants

Primary: Number of Participants With Complete Remission (CR) — 185 Participants

Primary: Maximum Tolerated Dose (MTD) of PGG Beta Glucan in Combination With Alemtuzumab and Rituximab Assessed by Analyzing the Number of Dose-limiting Toxicity Events (Phase I)…

Primary: Tolerability of Rituximab, Cyclophosphamide and Fludarabine in Patients With Previously Untreated CLL/SLL — 42 participants

Primary: Progression Free Survival (PFS) Based on Investigator Assessment — 106.9; 15.0 months — p=< 0.0001

Primary: Response Rate — 55.2 percentage

Primary: Progression-free Survival (PFS) — 981.0; 1212.0 Days — p=<.0001

Primary: Overall Response — 11; 23; 4; 5 participants

Primary: Number of Participants With a Complete Response After Treatment With Fludarabine & Rituximab Followed by Alemtuzumab — 38 participants

Primary: Complete Response (CR) — 8.3 Percentage of participants with CR — p=0.014

Primary: Complete Response Rate — 10 percentage of participants

Primary: Progression-free Survival (PFS) — 16.5; 11.1 Months — p=<0.0001

Primary: Number of Participants With an Overall Response — 23; 3; 26 Participants

Primary: PFS (Progression Free Survival) by Independent Review Committee (IRC), Limited to the Time of Primary Analysis 06 November 2013 — 8.1; NA months — p=<0.0001

Primary: Participants With Complete Remission (CR) at 24 Months — 3 Participants

Primary: MRD Cohort: 1-Year Disease-Free Survival (DFS) Rate in Confirmed uMRD Randomized Participants — 100.0; 95.3 percentage of participants — p=0.1475

Primary: Progression-free Survival (PFS) — 15.7; 28.9 months — p=<0.0001

Primary: Overall Response Rate (ORR) — 15; 30 participants

Primary: Participants With Objective Response — 0; 1; 13 Participants